Kairos Pharma (KAPA) Net Income towards Common Stockholders (2023 - 2025)
Kairos Pharma's (KAPA) quarterly Net Income towards Common Stockholders came in at -$1.6 million in Q2 2025, down 589.74% YoY from $329560.2 in Q2 2024, and down 4.13% on a QoQ basis from -$1.5 million in Q1 2025.
Kairos Pharma (KAPA) Net Income towards Common Stockholders (2023 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$1.6 million in Q2 2025.
- Quarterly Net Income towards Common Stockholders fell 589.74% year-over-year to -$1.6 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$5.2 million (down 48.25% YoY) and the FY2025 annual result came in at -$8.5 million, down 165.58% from the prior year.
- Net Income towards Common Stockholders fell to -$1.6 million in Q2 2025, from -$1.5 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$234000.0 in Q2 2024 to a low of -$2.1 million in Q4 2024.
- A 3-year average of -$1.0 million and a median of -$1.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders plunged 90.57% — and 2025, when it sank 589.74%.
- Tracing KAPA's Net Income towards Common Stockholders over 3 years: stood at -$1.1 million in 2023, then sank by 90.57% to -$2.1 million in 2024, then grew by 22.44% to -$1.6 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$1.6 million (Q2 2025), -$1.5 million (Q1 2025), and -$2.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Kairos Pharma | 5.50 Mn | 168,380.07 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -1.61 Mn |
| Mar 31, 2025 | -1.55 Mn |
| Dec 31, 2024 | -2.08 Mn |
| Sep 30, 2024 | -920,000.00 |
| Jun 30, 2024 | -234,000.00 |
| Mar 31, 2024 | -303,000.00 |
| Dec 31, 2023 | -1.09 Mn |
| Sep 30, 2023 | -302,000.00 |